| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8537444 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2018 | 46 Pages |
Abstract
DBS significantly alleviates depressive symptoms in TRD patients by targeting the SCG, VC/VS, MFB, and NAcc. Several adverse events might occur during DBS therapy, although it is uncertain whether some AEs can be linked to DBS treatment. Further confirmatory trials are required involving larger sample sizes.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Chanjuan Zhou, Hanping Zhang, Yinhua Qin, Tian Tian, Bing Xu, Jianjun Chen, Xinyu Zhou, Li Zeng, Liang Fang, Xunzhong Qi, Bin Lian, Haiyang Wang, Zicheng Hu, Peng Xie,